PLSE Stock — Pulse Biosciences Inc

Pulse Biosciences Inc (PLSE)

Updated October 16, 2026.

PLSE is a Stock. Total return is 965.5% over the past 10.4 years, 624.8 points ahead of SPY at 340.7%.

Pulse Biosciences is a bioelectric medicine company that develops and commercializes nanosecond pulsed-field ablation technology for treating benign skin lesions and cardiac conditions. The company's product portfolio includes the nPulse System for percutaneous skin treatments, surgical tools for atrial fibrillation ablation, and a cardiac catheter system designed for minimally invasive procedures. As an early-stage medical device company, it does not currently distribute dividends and is oriented toward growth investors rather than income-focused investors.

PLSE performance versus SPY

Price and return data through 2026-10-16.

Total return is 965.5% over the past 10.4 years, 624.8 points ahead of SPY at 340.7%. Over the past year its total return — price change plus distributions reinvested — is 152.9%. Its deepest 1-year drawdown was 30.5%.

PLSE key facts

Asset type

Stock

Asset class

Equity

Inception date

05/18/2016

Distribution frequency

None

Last close

$44.43 (as of 2026-10-16)

Market cap

$3,168,863,429

Average volume

327405.0

Beta

1.57

Payout ratio

0.0%

EPS

$-1.18

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PLSE risks and drawbacks

The deepest 1-year drawdown on record here is 30.5%.

Who may consider PLSE — and who may not

It is a weaker fit for investors who need monthly cash flow (PLSE does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on PLSE

• All tickers starting with P

Tagged: Healthcare.

Frequently asked questions